Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
Executive Summary
Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.
You may also be interested in...
Amgen Has Relatively Smooth Sailing In Q2 Despite COVID-19 Headwinds
Amgen reported a 6% year-over-year increase in second quarter sales despite pandemic-related declines for several drugs as newer product gains and Otezla righted a rocky ship.
Otezla Is Amgen’s Main Growth Driver As Net Drug Pricing Declines
Without the newly purchased drug, Amgen’s 2020 sales would be flat, but the company hopes to enhance its psoriasis market push with its combined offering of Otezla, Enbrel and biosimilars.
After Two Jury Verdicts, Court Finds Repatha Patents Invalid
Delaware district court rules patent claims for antibodies targeting PCSK9 are invalid for lack of enablement; saga to continue with Amgen appeal.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available Buy Reports
Need a specific report? 1000+ reports available Buy Reports